Conditions: Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
Keywords: Breast Cancer Letrozole Bone Mineral Density Bone Markers Serum lipid Postmenopausal
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 263
Healthy volunteers: no

Brief summary:
Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis.

This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.

Detailed description:

Arms:
arm 1: 2.5 mg once daily (q.d.)orally for 5 years arm 2: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.

Interventions: intervention 1: Letrozole intervention 2: Tamoxifen
Intervention descriptions: intervention 1: 2.5 mg tablets and supplied in bottles with 6-monthly supplies. intervention 2: 20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)

Protocol document: